Elon Musk, Ozempic and Mounjaro

‘Ozempic Santa’: Musk Reveals His Use Of Mounjaro In Latest Weight-Loss Drug Endorsement
Tesla chief Elon Musk dubbed himself “Ozempic Santa” in an X post on Christmas Day, marking the tech billionaire’s latest show of support for weight-loss drugs as he has pushed for making them more accessible to the general public.
Elon Musk Reveals He Lost Weight While Taking Mounjaro
Elon Musk posted a photo with the caption "Ozempic Santa" and revealed that he's taking Mounjaro for weight loss. Musk, who Donald Trump appointed to advise him on cutting government spending, has struggled with his weight.
Elon Musk says he prefers Lilly’s Mounjaro over Novo’s Ozempic
CEO's newfound preference for Eli Lilly's (NYSE:LLY) weight loss therapy Mounjaro over Novo Nordisk's (NVO) rival product Ozempic. Known as tirzepatide and semaglutide in generic terms, Mounjaro and Ozempic belong to a new class of diabetes drugs called GLP-1s,
Elon Musk Shows Off His Mounjaro-Fueled Slimdown — in a Santa Suit
Elon Musk showed off a slender figure on social media while wearing a Santa suit, revealing that he used Mounjaro to achieve his noticeable weight loss.
“Looking Good, Santa”: Elon Musk Admits To Using Mounjaro For Weight Loss In “Ozempic Santa” Post
Elon Musk uses the weight-loss drug Mounjaro, he newly revealed, as he jokingly referred to himself as “Ozempic Santa” in a Santa suit. Taking to the social media platform he owns, X (formerly known as Twitter),
Better Buy: Eli Lilly vs. Novo Nordisk. The Answer Is Becoming Abundantly More Clear.
Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...
Eli Lilly to end 2024 among best in Big Pharma; Novo among worst
As the year draws to a close, Wall Street is set to crown Eli Lilly (NYSE:LLY) among the best in Big Pharma, while Novo ...
Off-brand versions of Lilly weight loss drug must be pulled off market, could mean higher prices
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...
Lilly obesity drug Mounjaro to be offered in Britain's NHS after watchdog nod
Eli Lilly's obesity drug Mounjaro will be available through Britain's state health system for some patients from March, after ...
israelnewsonline11h
Eli Lilly is looking to extend its winning streak in the broad market to six years
Eli Lilly has surpassed that S&P 500 five years in a row when Wall Street recognized its enormous opportunity in obesity ...
Does This News From the FDA Make Eli Lilly a Buy for 2025?
In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...
Eli Lilly and Company (NYSE:LLY) Trading Down 0.2% – What’s Next?
Eli Lilly and Company (NYSE:LLY – Get Free Report) was down 0.2% on Thursday . The company traded as low as $791.50 and last ...
Eli Lilly, Novo Nordisk Stocks Rise. Only One Is Operating From a Position of Strength.
The obesity drug race is heating up in more ways than one.Eli Lilly, the world’s biggest pharmaceutical company by market ...
Eli Lilly: A Rare Buying Opportunity
Eli Lilly's key products, Mounjaro and Zepbound, dominate the U.S. weight loss market. Read more to see why I rate LLY stock ...
24/7 Wall St4d
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Beginning in March 2025, some patients in Britain will have access to Mounjaro, Eli Lilly’s obesity drug, through the National Health Service (NHS). This follows approval from the UK’s health ...
Is Now a Good Time to Buy the Dip in Eli Lilly Stock?
Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...